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“Except for monozygotic twins, each person’s genome is unique. All physicians will 
soon need to understand the concept of genetic variability, its interactions with the 
environment, and its implications for patient care … the practice of medicine has now 
entered an area in which the individual patient’s genome will help determine the optimal 
approach to care, whether it is preventive, diagnostic, or therapeutic.” 
   – Alan E. Guttmacher & Francis S. Collins, N Engl J Med, 2003 
 
 
“We live in a time of deep interest in – of not obsession with – the problems of health 
and disease … For those who are media vigilant, questions about the consumption of 
cholesterol (good or bad) … and a host of other specified “risk factors” are daily fare. 
Increasingly, we are told that new knowledge gives us new opportunities to take control 
of our health. With this new knowledge, however, come new responsibilities and a new 
set of moral expectations about health and disease.”  
   – Alan M. Brandt & Paul Rozin, Morality and health, 1997  
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ABSTRACT 
 
Heterozygous familial hypercholesterolemia (FH) is a genetic condition associated 
with increased risk of coronary heart disease (CHD). The overall aim of the thesis is 
to explore how individuals with FH perceive and manage their condition.  
 We did a qualitative interview study, based on semi-structured interviews 
with 40 women and men diagnosed with FH. Participants were recruited from the 
Lipid Clinic, Medical Department, Rikshospitalet-Radiumhospitalet HF, in Oslo, 
Norway, which is an outpatient clinic for metabolic lipid disorders. 
 The majority of participants convey images of individuals they considered to 
be likely victims of CHD, and portray the coronary candidate as someone who was 
different from themselves. The typical image was an unfit, middle-aged man, often a 
business man or a taxi driver. Women reports barriers in the health service related to 
diagnosis and treatment. Participants negotiate a personal and dynamic sense of their 
vulnerability to CHD, grounded in notions of their genetic and inherited risk. 
Participants’ perceived vulnerability could shift dynamically, due to changes in 
situational factors such as cardiac events in the family, illness experiences, or 
becoming a parent. Participants do not report guilt or shame for having FH, but they 
experience guilt and shame related to how well they manage their condition. Health 
professionals may cause feelings of guilt and shame in patients with FH. 
 Health professionals should recognize that patients may have moral and 
psychological reasons for distancing themselves from the “coronary candidate”. The 
stereotype of CHD as a men’s disease may result in barriers to diagnosis and 
treatment for women. In order to individualize clinical management of patients with 
FH doctors should elicit patients’ understanding of their family history of CHD and 
their perceived vulnerability to CHD. Health professionals should recognize 
patients’ preferences and use communicative strategies that diminish such 
experiences in their patients. 
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SAMMENDRAG [abstract in Norwegian] 
 
Arvelig høyt kolesterol, familiær hyperkolesterolemi (FH), er en genetisk tilstand 
som er forbundet med øket risiko for hjertesykdom. Målsettingen i denne 
avhandlingen er å utforske hvordan personer med FH opplever og håndterer sin 
tilstand.  
 Vi har gjort en kvalitativ intervjustudie, basert på individuelle 
semistrukturerte intervjuer med 40 kvinner og menn diagnostisert med FH. 
Deltakerne er rekruttert via Lipidklinikken, Medisinsk avdeling, Rikshospitalet-
Radiumhospitalet HF, som er en poliklinikk for metabolske lipidforstyrrelser.  
 De fleste deltakerne formidler bilder av individer de mener har økt risiko for 
koronar hjertesykdom, og de fremstiller den koronare kandidaten som en som er ulik 
dem selv. Det typiske bildet er en usunn, middelaldrende mann som gjerne var 
foretningsmann eller drosjesjåfør. Kvinner rapporterer at de møter hindringer i 
helsetjenesten relatert til diagnose og behandling. Deltakerne etablerer en dynamisk 
forståelse av egen sårbarhet for koronar hjertesykdom som er forankret i forståelse 
egen genetisk og arvelig risiko. Deltakernes oppfatning av egen risiko kunne endres 
over tid på grunn av endringer i faktorer som hjertekarsykdom i familien, 
sykdomserfaringer, eller ved at man ble foreldre. Deltakerne rapporterer ingen 
skyld- eller skamfølelse for at de har FH, men opplever skyld og skam knyttet til 
hvor godt de håndterer tilstanden. Helsepersonell kan vekke følelser av skyld og 
skam hos pasienter med FH. 
 Helsepersonell bør anerkjenne at pasienter kan ha moralske og psykologiske 
grunner for å distansere seg fra det typiske bildet av en person med økt risiko for 
koronar hjertesykdom. Det stereotype bildet av koronar hjertesykdom som en 
tilstand som rammer menn kan føre til at kvinner opplever diagnostiske og 
behandlingsmessige hindringer. For å kunne skreddersy den kliniske håndteringen 
av pasienter med FH bør leger ha innsikt i hvordan pasienten forstår belastningen for 
hjertesykdom i egen slekt og hvordan de forstår sin egen sårbarhet for hjertesykdom. 
Helsepersonell bør anerkjenne pasientens preferanser og anvende samtalestrategier 
som reduserer erfaringer av skyld og skam hos pasienter. 
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PREFACE 
 
One night, when I was 20 years old, my father was struck by nausea and a severe, 
squeezing pain in the stomach and chest. He phoned the casualty clinic. He did not 
have pain radiating down the left arm, and his case was regarded as an acute 
abdominal condition. He passed away while waiting for the doctor, 62 years old, 
from what was later diagnosed as an inferior myocardial infarction.  
This incident occurred in 1991 when I was in the middle of the first year of 
my medical studies. The death of my father made me reflect on my own possible 
hereditary susceptibility to heart disease, and it also made me reflect on how health 
professionals depend on diagnostic categories and stereotypes to interpret symptoms 
and to organize medical knowledge and clinical work. This experience was an 
important reason for my interest in the concept of risk and how people reflect on and 
manage uncertainties and risks of future suffering. I therefore dedicate this thesis to 
the memory of my father Alf.  
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1.  INTRODUCTION 
 
“When you hear hoofbeats behind you, don’t expect to see a zebra” is an aphorism 
that warns doctors against the danger of thinking about rare conditions at the 
expense of the most common and obvious causes of symptoms or clinical findings 
(1). With respect to coronary heart disease (CHD), the condition known as familial 
hypercholesterolemia (FH) is likely to be classified as a zebra. 
 April 14st, 2003, The International Human Genome Sequencing Consortium 
announced that the Human Genome Project had been completed. An article in New 
England Journal of Medicine declared that we have entered a new area of “genomic 
medicine” in which molecular biology will transform clinical practice (2). Genomics 
refers to the study of not only single genes, but of the functions and interactions of 
various genes. This “molecularization of medicine”, a phrase used by Rheinberger 
(3), has led to new insight about genetic aspects of atherosclerosis and CHD (4), and 
there appears to be an ongoing “geneticisation” of CHD in clinical practice (5). 
Some authors claim that we are entering an area “in which FH might very well 
constitute a unique example of what “the zebra can tell us about the horse”” (6).  
 This thesis will look at what the zebra can tell about the horse. Its overall aim 
is to explore how individuals with FH perceive, understand and manage their 
condition. I will explore what the experiences of individuals with FH can tell about 
what it means to be diagnosed with a cardiovascular risk in the genomic area. These 
experiences will need to be situated within the history and management of CHD in 
general, and therefore I will also address what the horse can tell about the zebra.  
 I will not be able to cover all aspects of living with a genetic risk of CHD. I 
have chosen to focus particularly on how patients with FH perceive and manage 
their own risk, and therefore I will not explore issues such as family planning among 
patients with FH, parental responsibilities, genetic testing of family members, and 
issues concerning life insurance. 
  
1.1 Coronary heart disease 
CHD is caused by atherosclerosis in the coronary arteries and is the cause of seven 
million deaths annually and is one of the leading causes of lost life years worldwide 
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(7). In Norway, CHD accounts for 18% of deaths in men and 15% of deaths in 
women (8). Atherosclerosis is a mulitfactorial disease, and about 300 risk factors 
have been reported in the literature (9). Risk factors are typically classified as either 
modifiable, such as elevated serum lipids, smoking habits, high blood pressure, 
obesity, and diabetes, or nonmodifiable, such as age, gender, genetic susceptibility, 
and possibly also birth weight. Risk factors tend to cluster in individuals. Blood lipid 
disorders have a principal role in the pathogenesis of CHD and have been 
characterized as “the pivotal CHD risk factor” (9). There are several lipid disorders, 
including FH (10, 11). As this thesis explores CHD from the perspective of patients 
with FH, I will provide a brief overview of disorders in the cholesterol metabolism. 
 
1.2  Cholesterol as cardiovascular risk factor 
Hypercholesterolemia refers to a condition characterised by elevated levels of serum 
cholesterol. Cholesterol is a sterol (a combination of steroid and alcohol). The name 
originates from the Greek “chole” (bile) and “stereos” (solid), and the chemical 
suffix “-ol” for an alcohol. Cholesterol was isolated in solid form from gallstones in 
1784, but Chevreul, a French chemist, is credited with the initial discovery of 
cholesterol (or “cholesterine”) in 1815 (12, 13). In 1913, the Russian pathologist 
Anitschkow found that rabbits fed with cholesterol developed atherosclerosis and he 
claimed that there was a correlation between hypercholesterolemia and 
atherosclerosis (14). In the 1940s, Keys conducted an epidemiological worldwide 
survey in populations whose diets varied in fat content (15). He found a correlation 
between high dietary intake of fat and increased cholesterol levels in the populations 
he had studied. Keys also suggested a causal relationship between the percentages of 
fat in the diet and the rate of CHD. Keys’ findings caught the media’s interest, but 
there were scientists who questioned his findings and made efforts to pull 
cholesterol back into the research laboratories (15). Until the early 1950s many 
researchers and clinicians perceived CHD as a chronic, degenerative disease that 
could not be prevented. 
 Results from The Framingham Heart Study, an ongoing follow-up study of 
the population in the city of Framingham in Massachusetts which was initiated in 
1948, suggested in 1961 that high cholesterol levels preceded the development of 
CHD and increased the risk of CHD (16). However, as these results were generated 
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in an observational study, controversies surrounding cholesterol went on for decades 
until intervention trials, such as The Multiple Risk Factor Intervention Trial 
(MRFIT), suggested in the 1980s that a cholesterol-lowering diet could reduce the 
risk of CHD (10). In 1988 the National Cholesterol Education Programme in USA 
launched the “Know your Number” campaign and recommended that all adults 
should have their cholesterol tested. By the end of 1980s the campaign had spread to 
other countries in the Western world, including Norway. Cholesterol still remained a 
controversial issue in the early 1990s because researchers were uncertain about the 
effect of cholesterol-lowering therapy on overall mortality (10). In 1994, it was 
showed that the overall mortality was reduced in the group who received 
cholesterol-lowering medication and that this was achieved without any increase in 
mortality of other causes (17). It is now documented that lowering serum cholesterol 
by means of diets or medication reduces morbidity and mortality of CHD without an 
increase in mortality from other causes (11), although cut-off points for intervention 
are vividly discussed.  
 
1.3  Cholesterol and its metabolism 
Cholesterol is a major building block in cell membranes and it is also precursor of 
steroid hormones and of bile acids (10). Cholesterol in its pure form is insoluble in 
blood, but lipoproteins make it soluble in the form of a lipid droplet in which the 
insoluble part is turned inwards into the core of the particle. Different types of 
lipoproteins serve to transport absorbed dietary fat, endogenously synthesized 
cholesterol and fatty acids (triglycerides). Cholesterol and triglyceride (TG) 
synthesized in the liver are secreted into the circulation in very low-density 
lipoprotein (VLDL) particles. The TG component is hydrolysed by the enzyme 
lipoprotein lipase in peripheral tissues and is released from the particle. The VLDL 
remnant is either removed from the circulation by the liver or metabolized to low-
density lipoprotein (LDL) by the enzyme hepatic lipase. LDL is a cholesterol-rich 
lipoprotein that transports cholesterol to peripheral cells. A high intake of fat, and 
especially saturated fat, increases the amount of VLDL particles and hence also the 
amount of LDL particles in the blood. Large numbers of LDL particles are 
correlated with atherosclerosis and CHD, and LDL-cholesterol is thus commonly 
referred to as “bad cholesterol”. High-density lipoprotein (HDL) particles transport 
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cholesterol back to the liver for excretion. A large number of HDL particles are 
correlated with better health outcomes, and HDL-cholesterol is thus often referred to 
as “good cholesterol”. 
 A LDL-receptor (sometimes abbreviated “LDLR”) on the cell surface 
recognizes a protein (apoprotein B-100) in LDL particles and this recognition is 
necessary for transport of LDL into the cell. Approximately 70% of LDL is removed 
from the circulation by the liver. The presence of LDL-receptor in the liver thus has 
a major influence on clearance of LDL from the circulation and thereby the amount 
of circulating LDL. A mutation in the gene that codes for the LDL-receptor may 
result in a failure to produce receptor or a reduction of receptor activity, which leads 
to accumulation of LDL-cholesterol in the blood. An individual with this condition 
has a specific genetic form of hypercholesterolemia, referred to as FH.  
 
1.4  Familial hypercholesterolemia 
FH is an inherited autosomal dominant disorder of lipoprotein metabolism and was 
described for the first time in 1873 (18). Harbitz published his first observations of a 
group of patients with this condition in 1925, but it was a Norwegian colleague 
Müller who noticed a correlation between hypercholesterolemia and early onset of 
CHD (19). The condition was previously known as “Müller-Harbitz’ disease”, but 
the correct term at present is familial hypercholesterolemia (FH). It was poorly 
understood until Brown & Goldstein in the early 1970s discovered that elevated 
LDL-cholesterol was the hallmark of FH (12). They discovered that the elevated 
LDL-cholesterol in this disease could be explained by reduced or absent activity of 
the LDL-receptor. The gene that codes for the receptor was later located to the short 
arm of chromosome 19. 
Heterozygous FH occurs with a frequency of 1 in 500 and the homozygous 
form occurs in 1 per million in most populations (20). In heterozygous individuals 
LDL-receptor activity is substantially reduced and in homozygous individuals 
receptor activity is virtually absent. In Norway, the diagnosis can be based on 
clinical and laboratory findings or be based on DNA-testing. More than 700 
mutations have been reported in the gene that codes for the LDL-receptor, but 
mutations are only detected in 30-50% of patients with a clinical diagnosis of FH 
(21, 22). A mutation in the gene for apolipoprotein B-100 (ApoB100), the molecule 
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that serves to bind LDL to the LDL-receptor, leads to the same phenotype as FH, but 
may be referred to as familial defective ApoB-100 (FDB). There are two sets of 
diagnostic criteria that are commonly used (appendix A) (20, 23).  
 Studies of mortality and morbidity of untreated men and women with FH are 
based on register-data and probably overestimate the risk of CHD (24). A recent 
cumulative risk estimate suggests that, left untreated, 50% of men aged 50 years and 
30% of women aged 60 years with the condition develop symptoms of CHD (20). 
Although FH is a monogenic condition (caused by a mutation in one gene only), 
there is a wide variety in the onset and severity of symptoms of CHD. The clinical 
severity has been found to vary considerable between families, with less variation 
within the same family (25). The literature suggests that the clinical severity is 
determined by environmental risk factors (24), other genetic factors, and by the type 
of mutation in the gene for the LDL-receptor (25-28). Mutations are classified into 
five or six categories, and while some mutations result in failure to produce any 
LDL-receptor protein, other mutations lead to impairments in binding capacity or 
other disturbances (26). Patients with so-called “null-alleles” where there is no 
production of LDL- receptor appear to have a higher risk of CHD (29). 
 LDL-cholesterol in untreated adults with FH is typically in the range of 5-10 
mmol/l and there is hence an overlap of cholesterol levels in individuals with FH 
and individuals in the general population. A healthy lifestyle is an important aspect 
of treatment and comprises ideal body weight, no smoking, moderate physical 
activity, and a healthy diet with a low amount of saturated fat and a cholesterol 
intake of less than 200 mg per day (30). A LDL-cholesterol level < 2.6 mmol/l is 
considered optimal, but such a goal is not obtainable for all patients due to limited 
efficacy of current LDL-cholesterol-lowering drugs and their side effects. There are 
three major groups of LDL-cholesterol-lowering drugs available. HMG CoA 
reductase inhibitors (“statins”) inhibit production of cholesterol in the liver, and it is 
the drug of first choice. Bile acid sequestrants (“resins”) bind bile acids and prevent 
bile acids containing cholesterol from being reabsorbed in the gastrointestinal tract. 
Ezetimibe is a lipid-lowering drug that inhibits absorption of cholesterol from 
dietary and biliary sources. 
 An international panel on management of FH has listed eight major risk 
factors for cardiovascular disease in patients with FH (30):  
 19 
 
• Age (men > 30 years, and women > 45 years or postmenopausal 
• Cigarette smoking: active smokers 
• Family history of premature CHD (CHD in male first degree relative < 55 
years or in female first-degree relative < 65 years) 
• High blood pressure (> 140/90 mmHg) 
• Diabetes mellitus 
• Very high LDL-cholesterol (> 8.5 mmol/l) 
• Low HDL-cholesterol < 1.0 mmol/l 
• Lipoprotein (a) > 60 mg/dl 
 
Patients can be categorized into three groups regarding ten-year risk of 
cardiovascular events. With no major risk factors the risk is low, with one major risk 
factor the risk is moderate, and with two or more major risk factors, or if the patient 
has non-symptomatic atherosclerosis or clinical cardiovascular disease, the risk is 
high. Individuals with FH do not score lower on quality of life compared with 
controls who do not have hypercholesterolemia (31, 32).  
 
1.5  Professional and lay epidemiology of heart disease 
The Framingham Heart Study was launched in 1948 with the aim of understanding 
more about causes of CHD. While scientists had previously searched exclusively in 
the laboratory for cues about causes, the Framingham study was a population based 
study. The investigators coined the term “risk factor” (16) which proved to be an 
essential conceptual achievement in what has been referred to as the “risk factor 
approach” in epidemiology (33).  
 A landmark paper from The Framingham Heart Study in 1961 declared: 
“from a study of the characteristics of persons who develop coronary heart disease 
under observation in comparison with those who remain free of disease it is possible 
to determine the characteristics of susceptible individuals” (16). The Framingham 
investigators found that young women had a lower rate of CHD compared with 
young men and that gender was greater than any other risk factor (16). Additionally, 
numerous epidemiological studies of cardiovascular risk factors provided evidence 
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that biological traits such as elevated serum cholesterol, blood pressure, obesity and 
diabetes were associated with increased risk of CHD (10).  
 In 1959, Friedman and Rosenman claimed that a certain behavioural pattern, 
called “type A behaviour pattern” or “coronary prone personality”, was associated 
with increased risk of CHD (34). A series of publications during the following 
decades indicated an increased risk of CHD in individuals with a behaviour 
characterised by excessive drive, competition, meeting deadlines, a desire for 
recognition and advancement. Within this model, CHD was seen as a psychosocial 
disease and as a consequence of people’s worries and strains in modern society (33, 
34). A bestselling book entitled “Type A behaviour and your heart” was published 
in 1974 (35). During the late 1970s, however, negative studies that investigated the 
type A hypothesis appeared more often than positive ones, and the interest in the 
type A behaviour as risk factor of CHD declined (33, 36). 
 How was epidemiological knowledge about CHD received by the lay public? 
How did lay people make sense of cardiovascular risk? How did lay people explain 
coronary events? Questions such as these were the starting point for Davison et al 
who did fieldwork and qualitative interviews with 180 lay informants in three 
communities in different areas of the South of Wales during 1988 and 1989 (37, 38). 
The study team coined the term “lay epidemiology” for lay theories about “heart 
trouble” (38), and they found that the notion of “candidacy” or “coronary candidate” 
was essential in lay explanations of CHD.  
 A “candidate” was “a person who (for a variety of possible reasons) is seen 
as being at particular risk from the misfortune of heart disease” (38). Among some 
of the characteristics associated with the “candidate” are fat people, people who 
don’t take exercise and are unfit, red faced people, people with a grey pallor, 
smokers, people with a heart trouble in the family, heavy drinkers, people who eat 
excessive amounts of rich, fatty food, worriers (by nature), and bad tempered, 
pessimistic or negative people (37). The hereditary disposition to heart disease was a 
key characteristic of the candidate. Davison and colleagues found that lay 
individuals used their notion of the candidate as a tool to explain one’s own illness 
or other people’s illness and death from CHD and to predict one’s own or other 
people’s risk of being hit by CHD. Lay epidemiology explained unwarranted 
survivals and anomalous deaths through reference to “luck” or “unluck”. 
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 Davison and colleagues’ work on lay epidemiology has been criticised for 
ignoring gender. Emslie and colleagues conducted a qualitative study in 1997 and 
1998 with 61 informants among participants in a cross-sectional survey about 
cardiovascular and respiratory diseases in the West of Scotland (39). They found 
that accounts of coronary candidacy were structured by gender: “Whenever 
respondents talked about specific coronary candidates, they were invariably talking 
about men” (39). Later research on the lay epidemiology of CHD has explored the 
issue of gender and how individuals without increased risk of CHD reason about 
their medical family history (40, 41).  
 Research suggests that CHD has been perceived and represented in the public 
as a disease that affects men (34, 36, 39, 42, 43). We know little about how 
individuals at risk of CHD portray the coronary candidate and how they relate to 
their notion of the candidate. A better understanding of how patients at risk of CHD 
conceive and reflect on their notion of the coronary candidate may foster an 
improved clinical management. 
 
1.6  Gender and coronary heart disease 
Gender influences health and patients’ management of disease (44). Mortality rates 
for all leading causes of death in the Western world are generally lower for women 
compared with men for all ages, and women also use health care more frequently 
(45). Gender needs to be considered in clinical settings as well as in public health 
(45, 46). On the other hand, clinicians and researchers may essentialize gender and 
thus overlook that differences within groups may be more striking than between 
groups (46). 
 Women’s risks of CHD increases with age (47), and on average women 
develop symptoms of CHD one decade later than men. In Norway, 3557 men and 
3212 women died from CHD (ICD codes I20-I25) in 2004 (8). There has been a 
decline in mortality rates of CHD in Norway the last decades, and the decline has 
been higher for men than for women (8). The demography of CHD is changing in 
Western countries. A recent study indicates that more women than men are affected 
and that CHD has shifted from a disease of middle-aged men to a chronic condition 
of elderly women (48). 
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 Although women tend to use health care more often than men (45), the 
literature suggests that women are diagnosed later and seek health care later than 
men for symptoms of CHD (49). Research also suggests that women are less likely 
to receive lipid-lowering medication and to have a coronary revascularization 
procedure when diagnosed with CHD (50-54). Some studies find no gender 
differences (55, 56), and it has been argued that gender differences may be a result 
of unadjusted age-effects and poor study design (57). A recent study that adjusts for 
age and previous risk factors found a significant gender bias in clinical management 
in disfavour of women (58). The impact of gender on clinical management of CHD 
and cardiovascular risk factors varies with the patient’s age (59). The overall picture 
appears to be multifaceted. 
 A gender difference in the management of CHD and risk of CHD may be 
explained along three axes: biological differences between women and men, lack of 
knowledge in women or reluctance to perceive oneself as someone at risk, and the 
existence of gender-specific barriers in the health service.  
 There is evidence that that men and women differ in the clinical presentation 
of cardiovascular symptoms and that CHD may be more difficult to diagnose in 
women (47, 60, 61). Research suggests that most women do not see CHD a 
substantial health concern and that they have little knowledge about their risk (62, 
63). A qualitative study suggests that women’s delay to seek care and their treatment 
decisions are linked to broader social and structural constraints and obligations (63). 
Research indicates that the candidate for CHD is often portrayed as a man and that 
women with symptoms of CHD adopt risk assessment strategies that enable them to 
conceptually distance themselves from risk of CHD by attributing risky lifestyle 
behaviour to men (64).  
 A study that investigated barriers to uptake of services for CHD in UK 
identified barriers such as patients’ fear of hospitals, patients’ denial of symptoms, 
and diagnostic confusion in the health service (65). No barriers in this study were 
specifically related to gender. An interview study with young women diagnosed 
with CHD found that women had experienced that their symptoms of CHD were not 
recognized in the health service (66). 
 Biological differences, patients’ distancing from risk of CHD, and barriers in 
the health service may all be important explanations for gender differences in the 
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clinical management of CHD. Little is known about how women at risk of CHD 
experience the health service, and what barriers they may experience to diagnosis 
and treatment. 
 
1.7 Perceived vulnerability  
There are various approaches to the study of how people perceive risk. 
Psychological research on risk perception originated in empirical studies of 
probability assessment and has been referred to as “the psychometric paradigm” (67, 
68). This approach uses psychophysical scaling and multivariate analysis techniques 
to produce quantitative representations of how people perceive risk.  There is also a 
considerable literature that studies how people perceive risk using qualitative 
methodology (69-71). “Perceived vulnerability” is a notion that has been used to 
denote patients’ perceived risk (72). Perceived vulnerability corresponds with 
“perceived susceptibility” which is a component of the health belief model (HBM) 
that was developed in the 1950s and has been used to explain health related 
behaviour (73, 74). Perceived vulnerability can be studied in quantitative terms or in 
qualitative terms. According to HBM, behaviour change requires that people must 
feel threatened by their behaviour or condition and believe that a change will result 
in a valued outcome at acceptable cost. The model contains various components 
which are used to explain and predict health-related behaviour:  perceived 
susceptibility, perceived severity, perceived benefits, perceived barriers, cues to 
action, and variables such as sociodemographic characteristics. Research suggests 
that perceived vulnerability is a strong predictor of preventive health behaviour (72, 
74). Several studies suggest that individuals make sense of their vulnerability to 
CHD in ways that differ from quantitative and numerical risk measures (37, 38, 71, 
75, 76). Heredity and notions about the coronary candidate appears to be important.  
 A study in Scotland found that people who say they have a family history of 
CHD are more likely to see themselves “at risk” of CHD and are less likely to 
smoke (77). A study in the Netherlands of risk perception among individuals who 
had been screened on FH found that a high actual risk was correlated with an 
increased perceived vulnerability to myocardial infarction and that a greater portion 
of these individuals used lipid-lowering medication (78). The perception of the risk 
of getting a myocardial infarction was affected by age, education, cholesterol level 
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and cardiovascular disease in the family. A qualitative interview study of 50 
individuals diagnosed with FH suggests that patients use their own general 
knowledge, clinical observations, and knowledge of personal family medical 
histories to make sense of risk (79).  
 More knowledge is needed about how individuals with FH resolve their 
vulnerability to CHD and how perceived vulnerability to CHD may change over 
time. There is significant variation in the severity of FH between families, and a 
better understanding of how patients with FH understand and resolve their 
vulnerability to CHD may foster an individualized and improved clinical 
management.  
 
1.8 Risk, guilt and shame 
Until the twentieth century the concept of risk had a limited use in sea navigation, 
gambling, mathematics and insurance (80). Beck has argued that the modern world 
is best understood as a “risk society” because the scientific and technological 
development, and modernity itself, has lead to numerous hazards that are difficult to 
calculate in terms of probabilities (81). The risk society affects individuals in two 
distinct ways. First, it increases the individual’s awareness of risks outside 
individual control, leading to uncertainty and unease. Second, a focus on individual 
risk leads to greater emphasis on individual agency. In modernity self-identity is 
more and more “reflexively organised”, and an individual’s biography, education, 
career, health, etc, is perceived as results of individual agency (82, 83). Awareness 
and knowledge of risk, dangers and hazards plays a vital role for individual 
decisions regarding the future and the modern self.  
 Identifying and classifying risk or risk factors has been central in 
epidemiology, and this “risk factor approach” has led to a “risk epidemic” in 
medical journals with an increasing production of knowledge about health risks 
from the 1960s and onwards (84). The body has become a primal site for discourses 
on health risks in the Western health culture (85). Health and fitness have become 
important values that are pursued in order to express self-control and are used as 
social tools to convey symbolic resources (86, 87). Health messages such as to stop 
smoking, to eat a healthy diet, to drink only moderate amounts of alcohol and to take 
regular exercise are daily fare in the media. An occupation with risk and preventive 
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health measures pervades modern medicine and raises a series of ethical dilemmas 
and questions concerning when and what to test for, and if or how health risks 
should be managed, treated or prevented (88). 
 Douglas has argued that the language of risk has become a substitute for the 
language of danger, and she sees a new blaming system emerge under the banner of 
risk reduction (89). The notion that the individual is responsible for their own health 
is wide-spread in western societies (90, 91), and to take a risk may involve 
transgressing a moral border and threatening social structure (92). Marantz has put it 
like this: “Have we reached such a point in our “health conscious” society that every 
individual who suffers an illness classified as “preventable” must bear the burden of 
responsibility for that illness? Why isn’t it possible to just get sick without it also being 
your fault?” (93). 
 A negative effect of health promotion is that people may feel anxiety, fear, 
guilt and shame (94, 95). Research shows that feelings of guilt and shame may 
influence patients’ health-seeking behaviours and the patients’ relationship with 
health professionals (96, 97). Guilt and shame may have positive effects such as to 
motivate patients to health-related behaviours, but may also have a negative effect 
by causing anger, self-blame or depression (98, 99). Guilt and shame are connected, 
but are usually distinguished as two separate emotions. Guilt is a self-directed anger 
over a violation of a norm, whereas shame is linked with anticipated or actual 
disapproval from others (98). One may say that guilt is caused by something one has 
done, while shame is related to something one is. Research indicates that patients 
may experience guilt or shame if they have been diagnosed with a potentially 
discrediting condition such as CHD (97).  
 Research suggests that patients diagnosed with FH may feel guilt if they fail 
to comply with treatment recommendations (100). An understanding of the 
psychological, moral and social aspects of living with such a genetic risk in the 
context of late modern health culture may improve management and reduce health 
professionals’ risk of inadvertently causing experiences of blame and shame in 
patients.  
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2.  AIMS OF THE STUDY 
 
The overall objective of the study is to explore how individuals with familial 
hypercholesterolemia (FH) perceive, understand and manage their condition. This 
thesis has four specific aims: 
 
• Explore how patient at risk of coronary heart disease (CHD) portray candidates 
for CHD  
• Explore barriers in the health service to diagnosis and treatment experienced by 
women at increased risk of CHD  
• Explore how patients diagnosed with heterozygous FH understand and perceive 
their vulnerability to CHD 
• Explore patients’ experiences of guilt and shame with regard to how they manage 
FH  
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3. MATERIAL AND METHODS 
 
3.1  Participants 
The empirical data in this study were generated in semi-structured interviews with a 
sample of participants diagnosed with familial hypercholesterolemia (FH) according 
to the Simon Brome Register Group definition of FH (appendix A) (20, 23). 
Participants were recruited from Lipid Clinic, Medical Department, Rikshospitalet-
Radiumhospitalet HF, which is a specialist clinic for metabolic lipid disorders in 
Oslo, Norway. The clinic has a scheme for diagnosing and treating patients with FH. 
Patients were referred to the clinic for diagnosis and evaluation based on their 
elevated lipid values and their family history of hypercholesterolemia and coronary 
heart disease (CHD). The Norwegian health service is predominantly publicly 
financed and equal access according to need is a pivotal principle. 
 We used a purposeful sampling strategy and aimed for a sample of relatively 
young participants with a diversity regarding social background, family history of 
CHD, and time since diagnosis. We anticipated that having symptoms of CHD 
might influence how participants perceived and managed their condition and for this 
reason we recruited some participants who had experienced a myocardial infarction 
or had been diagnosed with angina pectoris. 
 Participants were approached through an invitation letter distributed to patients 
by health professionals at the clinic. The sample size of forty participants (20 men 
and 20 women) was a result of saturation in the data as consecutive interviews 
yielded diminishing returns in regard to new information. The mean age for 
participants was 31 years. Seven participants had developed symptoms of CHD. 
Further characteristics of the sample are shown in appendix B. 
 
3.2  Interviews 
The interviews were conducted in the period June 2000 until March 2002, lasted 
from 45 to 90 minutes, and were tape-recorded. Of the 40 participants, 30 were 
interviewed in the interviewers’ office, eight in the interviewee’s home, two in the 
interviewee’s work office, according to their own wish. 
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 My interview approach was inspired by Kvale’s principles for qualitative 
research interviewing (101). I used various strategies and questions to structure the 
dialogue, such as introducing questions, direct and indirect questions, specifying 
questions, silence and interpreting questions. My point of departure was an 
interview guide that was developed based on eight weeks of fieldwork in the Lipid 
Clinic where I engaged in informal conversations with patients and observed 
consultations between health professionals and patients. The interview schedule 
covered issues about health and disease, and addressed how participants perceived 
and managed their risk of heart disease (appendix C). I did not follow the interview 
guide strictly, but aimed at creating an atmosphere where interviewees were 
encouraged to talk freely about their experiences, views, and feelings. I used the 
interview guide to check that topics were covered. In addition I explored themes and 
hypotheses that emerged in subsequent interviews.  
 According to Rabinow, qualitative data do not represent “rocks, picked up 
and put into cartons and shipped home to be analyzed in the laboratory” (102). I use 
the phrase “data collection” with an understanding that data from research 
interviews are not collected like physical objects, but are generated in the dialogue 
between interviewer and interviewee. Still, qualitative data are not necessarily 
biased or without any truth value. In order to assess their validity, one needs to 
account for the circumstances under which the data were collected and one also 
needs to reflect on how the interviewer and the research context may have 
influenced the data (103). 
  
3.3  Interviewer’s role, background and perspectives 
In the interview setting I was particularly aware that participants should be 
encouraged to speak freely about their views and experiences. I presented myself as 
a “researcher with an interest in how it is to live with a genetic risk of heart disease”. 
I explained the aim of the study, and emphasized that I had no other role in the clinic 
than being a researcher. I also said that accounts of experiences with health 
professionals could be helpful in improving the health service and that the 
information they gave me would be treated with confidentiality. 
 My professional background is being a medical doctor with an academic 
degree in medical anthropology. During interviews some participants asked my 
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about my background, and in such cases I answered that I was a medical doctor who 
had also studied social science. I deliberately tried to avoid being perceived as a 
medical expert on their condition, and emphasized that my knowledge about CHD 
and FH was limited. Sometimes participants asked me to comment on medical 
questions, and in such cases I encouraged them to contact their doctor if they were 
concerned about their medication or had other worries concerning their condition. I 
chose this strategy in order to convey to participants that I was interested in their 
own views spoken out in their own words. 
 Some participants asked me why I was interested in doing research on patients’ 
experiences with FH. I never told participants about my own personal experiences, 
briefly described in the preface, because I feared that it would disturb the necessary 
distance between interviewee and interviewer and shift the attention towards me. 
The first interviewee asked me if I had checked my own cholesterol, and he was 
angry to hear that I had not taken a cholesterol test. Earlier, during the interview, he 
had used the expression “ticking bombs” about people who were unaware of their 
hypercholesterolemia. He convinced me to take a cholesterol test when he said: 
“You can’t fool people like me that you are seriously interested in people with FH if 
you don’t bother to take your health seriously and check up your own cholesterol!” 
A few weeks later I received the results from the test and was relieved to learn that 
my total cholesterol was well bellow 5 mmol/l. My first participant taught me a 
lesson that was important also from a methodological point of view – it was a good 
thing to have taken that test. It made it easier for me to listen to participants’ stories 
about premature cardiac deaths in their families, and their concerns and fears, 
without worrying about my own cholesterol level. 
 Malinowski claims that “foreshadowed problems” and theoretic perspectives 
are important resources in qualitative research: “[T]he more problems he brings with 
him into the field, the more he is in the habit of moulding his theories according to 
facts, and of seeing facts in their bearing upon theory... foreshadowed problems are 
the main endowment of a scientific thinker, and these problems are first revealed to 
the observer by his theoretical studies (104). I brought with me some “foreshadowed 
problems”, preconceptions, perspectives, and motivations into this project. Based on 
anthropological readings on health beliefs and the doctor-patient relationship, I 
expected to find that patients’ understanding of FH and CHD could differ from the 
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way these conditions were understood among doctors (105, 106). I thought that 
patients’ notions about risk would be somewhat different from epidemiological 
concepts of risk, and I expected to find variation among individuals in how they 
understood and related to their condition. I assumed that women and men could 
perceive and manage their condition somewhat differently. I was familiar with 
insights from Davison and colleagues’ work on lay epidemiology and I had a 
particular interest in exploring how patients with a genetic risk perceived their 
vulnerability to CHD (38).  
 I embarked on this research project with an interest in understanding more 
about patients’ experiences of living with risk of CHD, because I assumed that such 
knowledge could facilitate a better and individualized clinical management. I have 
been inspired by works within patient-centered and biopsychosocial medicine, in 
which it is key task for health professionals to recognize patients’ agendas and get 
insight into patients’ own appraisal of their health-related risks and resources (107-
111). 
 
3.4  Analysis 
I transcribed the tape-recorded interviews in verbatim, and these transcripts were 
analyzed qualitatively. I and a coauthor read ten transcripts independently and 
developed a coding frame for the analysis (appendix D). I coded all transcripts and 
used the qualitative research software N6 during the coding process (112). All 
collaborating researchers (coauthors) independently read the material (excerpts from 
interviews) organized under the code(s) that provided material for each study (paper 
I-IV). They then contributed in negotiating the final categories and their contents. 
The procedure for analysis we used was “systematic text condensation”, according 
to the principles of Giorgi’s phenomenological analysis (113), modified by Malterud 
(103, 114). The analysis followed four steps: (i) reading all the material to obtain an 
overall impression and bracketing previous preconceptions; (ii) identifying units of 
meaning, representing different aspects of the theme and coding for these; (iii) 
condensing and summarizing the contents of each of the coded groups; and (iv), to 
generalize descriptions and concepts about the specific theme for each study. Figure 
1 gives an overview of the data collection and analysis.  
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Figure 1. An overview of data collection and analysis. 
40 tape-recorded 
semi-structured 
interviews
40 transcripts
Independent reading 
of 10 transcripts
“Reports” for each code
(excerpts of text)
Codes (appendix D)
Coding of transcripts
“Memo” for each 
participant
Analysis: Summary of 
categories and findings 
in an “analysis 
document”, which were 
commented by all 
authors
Transcription
Writing and revision of 
manuscript/paper
English translation 
of illustrating quotes
 The findings and analysis were summed up in an “analysis document” that was 
used as a basis for writing and revision of each manuscript (paper I-IV). Quotes 
from the interviews were translated from Norwegian to English by me in the process 
of writing the papers. I had written a note (“memo”) with demographic information 
for each participant, observations from the interview setting, and a characteristic of 
main issues that emerged in each interview. I used these memos during all stages of 
the analysis and they proved to be very helpful tools that informed the analysis, and 
I consulted them if I needed any contextual information about ext excerpts or 
illustrating quotes.  
 
3.5  Ethical considerations 
Ethical approval for the study was obtained from The Regional Committee for 
Medical Research Ethics (Health Region East), Norway (reference: S-99053). 
Norwegian Data Inspectorate granted us permission to make a temporary register of 
participants in the study (reference: 9900510 LT/BHB, 9900510 LT/RH). All 
participants were informed about the purpose of the study, and that they could stop 
the interview at any time without giving a reason. Written informed consent and an 
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agreement that quotes from the interviews could be used anonymously were 
obtained from all participants. An interviewer who interview individuals at risk of a 
potentially fatal disease may impose risk awareness or increase the participant’s 
sense of vulnerability. I paid attention to interviewees’ emotional responses during 
our dialogue, and in a few of the interviews we came to a point where I chose to 
shift topic due to the interviewee’s response. The data were anonymized and health 
professionals at the clinic could not identify the interviewees when being presented 
with parts of the material. 
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4.  SUMMARY OF RESULTS 
 
 
4.1  Paper I 
Frich JC, Malterud K, Fugelli P.  
How do patients at risk portray candidates for coronary heart disease? A 
qualitative interview study.  
Scand J Prim Health Care 2007; 25: (in press)  
 
The aim of this paper was to explore how patients at risk of coronary heart disease 
(CHD) portray candidates for CHD.  
 We found that some participants believed that CHD could happen to anyone, 
while the majority conveyed detailed notions of persons they considered to be likely 
victims of CHD. Participants often portrayed the coronary candidate as someone 
who was different from themselves; the typical image was an unfit, middle-aged 
man, often a business man or a taxi driver. Some women said that they had to 
reconcile themselves to being at risk of CHD, since they at first had conceived CHD 
as a men’s disease. While some participants considered their notions to be valid for 
assessing people’s risk of CHD, others questioned how valid their notions were.  
 We conclude that doctors should recognize that distancing is a way patients 
cope with risk and that such a strategy may have psychological and moral reasons, 
and that when communicating about risk, doctors should take into account that 
patients’ notion of risk may differ from medical notions of risk.  
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4.2 Paper II 
Frich JC, Malterud K, Fugelli P.  
Women at risk of coronary heart disease experience barriers to diagnosis and 
treatment: a qualitative interview study. 
Scand J Prim Health Care 2006; 24: 38-43. 
 
The aim of this paper was to explore barriers in the health service to diagnosis and 
treatment experienced by women at increased risk of coronary heart disease (CHD).  
 The paper is based on an analysis of twenty women’s accounts of their 
experiences with the health service.  
 We found that women reported three specific barriers related to diagnosis 
and treatment of CHD. They had to struggle to take a cholesterol test; they 
experienced that their risk was being downplayed by doctors; and, that their 
symptoms of CHD were misinterpreted when they consulted doctors for evaluation 
and treatment.  
 We conclude that stereotyping CHD as a men’s disease may result in be 
barriers to diagnosis and treatment for women, and that doctors should ask the 
patient about the family history of CHD if a concern about heart disease is on the 
patient’s agenda.  
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4.3 Paper III 
Frich JC, Ose L, Malterud K, Fugelli P.  
Perceived vulnerability to heart disease in patients with familial 
hypercholesterolemia: a qualitative interview study.  
Ann Fam Med 2006, 4; 198-204.  
 
The aim of this paper was to explore how patients diagnosed with heterozygous 
familial hypercholesterolemia (FH) understand and perceive their vulnerability to 
CHD.  
 We found that participants negotiated a personal and dynamic sense of 
vulnerability to coronary heart disease, grounded in notions of their genetic and 
inherited risk. Participants developed a sense of their vulnerability in a two-step 
process. First, they consulted their family history to assess their genetic and 
inherited risk, and for many a certain age designated when one could expect to 
develop symptoms of CHD. Second, they negotiated a personal sense of 
vulnerability through comparisons between themselves and family members. In 
these comparisons they accounted for individual factors such as gender, cholesterol 
levels, use of lipid-lowering medication, and lifestyle. Participants’ personal sense 
of vulnerability to CHD could shift dynamically, due to changes in situational 
factors, such as cardiac events in the family, illness experiences, or becoming a 
parent.  
 We conclude that doctors should elicit patients’ understanding of their family 
history and their personal vulnerability, in order to individualize clinical 
management. 
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4.4 Paper IV 
Frich JC, Malterud K, Fugelli P. 
Experiences of guilt and shame in patients with familial hypercholesterolemia: 
a qualitative interview study.  
Submitted.  
  
The aim of this paper was to explore patients’ experiences of guilt and shame related 
to management of familial hypercholesterolemia (FH).  
 We found that participants did not feel guilt or shame for having the condition, 
but they usually made efforts to convey to others that their raised cholesterol was 
inherited and was not caused by an unhealthy lifestyle. Participants reported guilt if 
they had violated their standards for dietary management. They could feel guilt and 
shame if the result of a cholesterol test was not favorable. Though some participants 
had experienced health professionals as too persistent and eager, most were satisfied 
with how they had been met. One group, however, reported experiences of 
frustration, humiliation and shame in consultations.  
 We claim that recognition of patients’ preferences and readiness for lifestyle 
counseling may reduce the health professionals’ risk of unintentionally inducing 
guilt and shame in patients, and that health professionals need to be aware of 
patients’ vulnerability to experience guilt and shame and should use communicative 
strategies that diminish such experiences in their patients. 
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5.  DISCUSSION 
 
5.1 Methodological considerations 
Reflexivity  
We approached the material as medical doctors with an interest in exploring how 
patients diagnosed with familial hypercholesterolemia (FH) perceive and manage 
their condition. We chose to focus on four specific themes (paper I-IV). 
 My preconceived ideas about lay epidemiology of coronary heart disease 
(CHD) was confirmed, but I was somewhat surprised that participants’ notion of the 
coronary candidate appeared to be similar to that of the general public. When I 
planned the project, I did not expect that gender would become such an important 
theme. During the first interviews issues related to gender, and particularly women’s 
experiences of being at risk of CHD, was a theme that spontaneously emerged in 
participants’ accounts. By focusing on women (paper II) I may have overlooked 
issues regarding men’s experiences with the health service. When analyzing the data 
I found hardly any talk about barriers to diagnosis and treatment among men. Being 
a man, I may have influenced how both women and men talked about their views, 
experiences, health and risk-status. Perhaps women were more willing to talk openly 
about their frustrations and experiences of barriers in the health service? The 
literature indicates a gender difference in disfavor of women and for this reason we 
investigated women’s experiences (paper II), based on data from the interviews with 
women only. 
 I was theoretically influenced by the health belief model (HBM) and the 
notion of “perceived vulnerability”. I was interested in exploring the way in which 
participants’ reasoned about their vulnerability and the factors that could influence 
their perceived vulnerability over time (paper III). The participants in our sample 
have different socioeconomic backgrounds and educational levels, and the analysis 
may have overlooked the possible impact of such factors on participants’ perceived 
vulnerability. Paper III suggests that the risk of CHD may be given lower priority in 
competition with psychosocial constraints or other more urgent obligations and risk. 
The same may be true for people who experience socioeconomic deprivation.  
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Internal validity 
Participants in this study were recruited from a specialist clinic and were all 
diagnosed with FH. We have no indications that there is a selection of worriers or 
patients with multiple risk factors in our sample, but there has probably been a 
selection towards individuals who were in favor of medical treatment. Individuals 
who were not motivated for medical treatment of their lipid disorder would not have 
enrolled as patients, and this may explain why we found few participants in our 
sample who conveyed a fatalist attitude to their condition. 
 Referral and regular monitoring in a specialist clinic may have modified 
patients’ understanding of their condition and they may have become more aware of 
the importance of heredity and their family histories of CHD.  
 A majority of participants in our sample were young and asymptomatic 
(appendix B). Older participants in the study provided valuable insights about how 
growing older and experiencing symptoms of CHD could influence perceived 
vulnerability to CHD. 
  Paper I and III addresses participants’ own notion of the coronary candidate 
and factors that influence perceived vulnerability to CHD. Individual semi-
structured interview is a suitable and valid tool for exploring such phenomena. Paper 
II and paper IV explore patients’ experiences with the health service. In these two 
papers, participants’ accounts are used as an indirect source of social reality, which 
is mirrored through patient’s experiences and felt disagreements with health 
professionals (figure 2). We have no data on what actually took place in the medical 
encounters that our participants refer to. One may thus speculate whether there has 
been a selection to the clinic of patients with negative experiences with the health 
service, but the reverse may also be true (paper II). One may also question the 
validity of participants’ accounts. The patterns we identified are consistent in the 
material and there is nothing in the data suggesting that we should distrust their 
accounts. Further, data about how participants experience the health service are 
valid in their own terms, as the patient’s experience is an important clinical outcome 
measure (115). 
Issues concerning guilt and shame emerged as themes in the interviews 
(paper IV). It was not an easy theme to address explicitly, because people seldom 
display their perceived failures. One has to expect that individuals will try to present 
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themselves in the best possible way to an interviewer. Further, admitting 
experiences of guilt or shame may actually induce feelings of shame in people, 
because such emotions are often experienced as shameful (96). People may express 
guilt and shame in other terms. We have interpreted participants’ frustrating 
experiences as indication of an experience of shame in the clinical encounter even 
though they seldom talked about shame explicitly (paper IV). 
Figure 2. An overview of papers in the thesis. The dashed boxes indicate social phenomena that are 
explored indirectly through participants’ accounts.
Paper I Paper II
Patients’ notion of 
the coronary 
candidate
Women’s experienced 
barriers to diagnosis and 
treatment
Doctors’ notion of the 
coronary candidate and 
clinical management
Doctors and health 
professionals’ clinical 
management
Patients’ experiences of 
guilt and shame related to 
management of FH
Patients’ perceived 
vulnerability to coronary 
heart disease
Paper III Paper IV
 
External validity  
I stated that this thesis aims at exploring what the zebra could tell about the horse, 
and at the same time address what the horse can tell about the zebra. Some findings 
are valid only for “zebras” – patients diagnosed with FH who are treated in a 
specialist clinic. Our study suggests that patients with FH in some respects are 
perceived and managed as horses in general practice and in the health service in 
general, and that in particular women may experience barriers to diagnosis and 
treatment (paper II). We also found that individuals with FH resolve their 
vulnerability to CHD by drawing partly on the notions of risk in lay epidemiology 
(paper I) and on their family history of CHD (paper III). Some findings may be valid 
for “horses” – patients at risk of CHD in general – though we should be cautious 
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about stating that they are transferable to other clinical settings without further 
consideration. Our findings about coronary candidacy among patients with FH 
(paper I and II) may be transferable to patients at risk of CHD in general. Barriers to 
diagnosis and treatment are likely to be experienced also by women who do not 
have a specific genetic risk of CHD (paper II). Our findings about the role of family 
history in patients’ understanding of their vulnerability to CHD (paper III) may be 
relevant for people who do not have a specific genetic risk of CHD such as FH. 
Previous research suggests that people use their family histories to assess their risk 
for common diseases such as CHD and cancer (71). Our findings concerning 
patients’ experiences of guilt and shame (paper IV) may be transferable to clinical 
settings in which health professionals manage patients with chronic conditions that 
require self-management and where communication about lifestyle and diets is part 
of the treatment.  
 
5.2 Does coronary candidacy matter?  
Our study shows that patients diagnosed with a genetic risk of CHD convey notions 
of the coronary candidate (paper I). There are striking similarities between the image 
of the coronary candidate among individuals at risk and individuals without a known 
risk of CHD (38, 39). Public imagery of the candidate appears to be important for 
how individuals at risk perceive CHD. We found that both men and women 
distanced themselves from their notiom of the candidate, and we found that some 
women at risk experience that they have to reconcile themselves to being at risk of 
CHD, because they at first considered CHD to be a man’s disease (paper I). 
Distancing oneself from the coronary candidate may be a way of coping that relieves 
the sense of vulnerability and anxiety related to being diagnosed with increased risk. 
Such a strategy may be a moral statement that signifies that one takes the risk 
seriously, and it may also be a consequence of an insight that an individual with FH 
is different from other individuals who they think have a self-inflicted 
hypercholesterolemia (paper I, paper IV). 
 Research suggests that the quality of health care regarding diagnosis, referral 
and treatment of CHD is lower for women compared with men (51, 52, 54, 58). Our 
study of women’s experiences with the health service (paper II) suggests that a 
portion of doctors perceive CHD primarily as a men’s disease, and that this 
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influences doctors’ management of risk factors and symptoms of CHD in women. 
Women’s experienced barriers to diagnosis and treatment may be explained by a 
mismatch between women who are concerned about their risk and doctors’ 
stereotypes of the candidate. Previous research has found that doctors assess equal 
cardiovascular risks differently in women and man, and that there is gender bias 
disfavouring women (116). 
 Research suggests that women wait longer than men before they contact the 
health service with symptoms of CHD (49, 117). Furthermore, women may 
contribute to lower quality of care by distancing themselves from cardiovascular risk 
(63, 64). An understanding of gender inequalities of health care need to consider 
both women’s distancing to risk (paper I) and experienced barriers (paper II). 
Coronary candidacy seems to be a common denominator for an understanding of 
both lay and professional management of CHD.  
Coronary candidacy matter in clinical settings because such beliefs most 
likely have an influence on how cardiovascular risks and symptoms are being 
interpreted and managed. Mongomery claim that medical knowledge in clinical 
practice is structured around narratives and analogical reasoning (1). Diagnostic 
stereotypes are helpful tools that organize clinical reality, but they may also 
influence doctors’ capability to recognize a pattern that does not fit a stereotype. I 
think doctors may manage patients better if they are conscious about how coronary 
candidacy may influence professional judgment and lay people’s health-related 
behaviors. Sounds clinical judgment is to be able to recognize the sound of 
hoofbeats, but to know when to think about zebras and to reassess your initial 
diagnostic judgment when think you hear a horse behind you. Sound clinical 
judgment involves the skill to recognize that not all horses are alike. 
Future research should explore how doctors reason about cardiovascular risk, 
and particularly investigate how notions of coronary candidates may influence 
clinical management. Coronary candidacy matter in public health because lay 
epidemiology partly echoes how professional epidemiology portrays the coronary 
candidate. As the demographics of CHD are changing and more women are affected 
(48), there is a need for health promotion and information campaigns addressing 
cardiovascular risk in women. Future research should monitor and explore how 
coronary candidates are portrayed in the public.  
 42 
 European Society of Cardiology has recently launched the campaign 
“Women at heart” which is an initiative with the aim of “highlighting to medical 
professionals the growing burden and under-appreciation of women’s heart disease 
and promote improved handling of women at risk of cardiovascular disease in 
clinical practice” (118, 119). An increased focus on women and women’s 
experiences does not leave out that there may be specific issues and challenges 
related to how men perceive and manage cardiovascular risks or symptoms. A 
gender-sensitive approach to management of patients with cardiovascular risk of 
disease is needed, both for women and men (120).  
 
5.3  How to deal with family histories? 
A family history of premature coronary heart disease is one of the most important 
determinants of early and severe cardiac events in individuals with FH (26). The 
clinical severity of FH varies considerably between families, and information from 
the family history is usually more relevant than average risk estimates when 
assessing an individual patient’s risk. In paper III we explore how patients 
diagnosed with FH understand their vulnerability to CHD. Previous research 
suggests that people consult their family histories to assess risk by counting affected 
relatives, and use similarities in looks, personality or mannerism to assess whether 
they have inherited a certain constitution or disposition (40, 121-124). In our study 
we found that participants seldom made reference to physical or mental similarities 
(paper III). “Family statistics”, the age-pattern for onset of CHD in a family, 
appeared to be an important predictive device for many participants. Our study adds 
to previous knowledge by demonstrating how patients diagnosed with FH develop a 
dynamic and personal sense of vulnerability to CHD, grounded in notions of their 
inherited risk. Paper II demonstrates that a patient’s family history can offer doctors 
clues to why an “untypical” patient seeks health care.  
 Previous research suggests that people in the general public emphasize heredity 
when reasoning about their risk of CHD (40, 121). Patients’ assessment of 
cardiovascular risks and their family histories of CHD may deviate from doctors’ 
assessment of risk (40, 76, 125, 126). A hereditary disposition to CHD is a risk 
factor also for individuals without FH. Doctors should therefore ask patients about 
their medical family histories and explore how patients understand their own 
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hereditary dispositions. There is need for more research on how information for 
patients’ family histories are recorded, interpreted, and managed in clinical practice, 
and there is also a need for research that investigate how individuals recount and 
perceive their family histories of common diseases (127). 
 At present there are genetic tests for over 1000 different diseases and 
conditions (128). Family history will nevertheless remain the first “screening test” 
before individuals are referred to genetic assessment and is a key to an 
individualized assessment of risk (129). In USA, the U.S. Surgeon General’s Family 
History Initiative was recently launched to increase the awareness of family history 
in relation to disease (130).  
 An increasing awareness about hereditary dispositions to disease in the 
population will probably pose a challenge for the health care system, and 
particularly for general practitioners. In Norway, patients are likely to consult their 
general practitioner first for an evaluation and assessment of their genetic 
vulnerability to disease. Are general practitioners prepared for this task? Rich and 
colleagues claim that there are substantial barriers to application of new genetic 
knowledge in general practice, and that it may be difficult to find time to obtain, 
organize, visualize, and analyze the patient’s family medical history (132). 
Wattendorf & Hadley argue that general practitioners ought to practice “family 
medicine” and that this involves constructing a three-generation pedigree for each 
patient (132). 
 An increased awareness about family history raises some dilemmas and ethical 
issues. An increased awareness of health risks may have psychological and social 
negative effects (88, 97, 100). Further, a portion of families are not biologically 
related and there may also be conflicts or lack of contact between family members. 
Doctors should be sensitive to such issues and need to recognize that it may not be 
possible or desirable to construct a three-generation pedigree for all patients. An 
increased emphasis on patients’ family histories may help doctors to detect and 
manage patients who are at high risk, but may lead to a “medicalization” of family 
relations. In clinical practice, doctors need to find a balance between possible 
benefits and costs for the patient and his or her family. 
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5.4  Communicating about risk 
There are several reasons why communication about risk is a challenge for doctors. 
First, it may not be clear what the actual risk is, and the doctor’s task is to 
communicate about uncertainty rather than a quantifiable risk. Second, patients’ 
understanding of risk may be different from medical and quantitative risk estimates 
(paper III, 69, 76, 133, 134). Third, the way risk is presented influence decision-
making in both doctors and patients (135-137).  
 A solution to some of these challenges has been a suggestion that the language 
of risk should be clarified and standardized (139). Numbers-needed-to-treat (NNT) 
is a format that has been promoted as a standardized tool for communicating 
quantitative risk and effect of medical treatment. Empirical studies indicate that both 
lay people and doctors misunderstand NNT (140). Though a standardized language 
of risk in terms of NNT or other formats may prevent misunderstandings and be 
helpful for communication between health professionals, such a language may not 
be helpful when communicating with patients. Steiner puts it like this: “As 
physicians, we need to become bilingual – that is, we must speak the language of 
populations as well as the language of individual patients.” (141). Doctors think the 
best strategy is to combine different formats (quantitative, qualitative, and visual) 
and accommodate to the varying needs, preferences and abilities of patients (142). 
 Our findings suggest that communication about cardiovascular risk in patients 
with FH should be individualized and be a two-way process that involves a dialogue 
that should aim at establishing mutual understanding and a common ground for 
decision-making about preventive measures and medical treatment. It is a major task 
is to establish a dialogue and ask questions that mobilize the patient’s personal 
health-related resources (110). On the basis of paper I and paper III, I have 
constructed a figure that illustrates the factors involved in communication about risk 
with patients diagnosed with FH (figure 3). The figure illustrates essential 
components of the patient-centered clinical method which aims at exploring both the 
disease and the disease experience, understanding the whole person, finding 
common ground for mutual understanding (111). 
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Patient’s knowledge about his 
or her medical family history
Patient’s family history of CHD
Patient’s health related
preferences, resources, and 
motivation for preventive 
measures and treatment
Patient’s perceived
vulnerability to CHD
Doctor’s medical assessment of 
the patient’s hereditary
susceptibility to CHD
Figure 3. Individualized communication about risk and health resources. Doctors need to consider the 
patient’s family history, other risk factors, the patient’s perceived vulnerability to coronary heart 
disease (CHD), and factors that influence patients’ perceived vulnerability (dashed box).
Communication about risk 
and health resources: 
establishing mutual 
understanding and common 
ground for decision making  
about preventive measures and 
medical treatment 
Doctor’s assessment of the
patient’s total risk of CHD  
Patient’s life situation (age, 
illness episodes, coronary events
in the familiy, social obligations)
Patient’s lipid status and other
risk factors for CHD
Notion of coronary candidate Social construction of 
the coronary candidate
Social construction of 
the coronary candidate
?
Patients’ motivation for preventive health behaviours increases if they are given 
personally relevant information rather than information about average risks (136). 
Doctors need to be sensitive to the individual patients’ preferences. An acquaintance 
with a patients’ psychosocial context, in addition to knowledge about how the 
patient understands his or her family history, can give important clues about a 
patient’s readiness for preventive behavior (paper III).  
 Future research should develop and evaluate methods and tools for recording 
and assessing family history information in clinical practice, and explore how 
doctors communicate about cardiovascular risk. There is also a need for need for 
research on methods and tools for dialogic and patient-centred communication about 
risk. 
 
5.5. Guilt and shame in the clinical encounter 
Communication about risk often involves discussing preventive health measures that 
concerns the patient’s agency, identity, and preferences, and there is a potential of 
blaming or shaming patients in the clinical encounter (paper IV). According to 
 46 
Davidoff, shame is “something so big and disturbing that we don’t even see it, 
despite the fact that we keep bumping into it.” (143). Berger coined the notion of 
“iatrogenic guilt” (144). Doctors and health professionals need to recognize patients’ 
vulnerability to experience guilt and shame, and use communicative strategies that 
are likely to diminish such experiences in patients (96, 98, 111). Enhancing the 
patient-doctor relationship and being realistic are two components of the patient-
centered clinical method (111). The following rules of thumb are based on such a 
patient-centered approach and on literature about shame and guilt in the clinical 
encounter (96, 98, 144, 145, paper IV):  
 
• Doctors and health professionals should elicit patients’ readiness for 
counseling and health education and respect the patients’ health-related 
preferences.  
• One may diminish a patient’s guilt by emphasizing the uncertainties with 
self-management, and tell the patient that there may be a rise in cholesterol or 
a worsening of other risk factors even with the best efforts of the patient.  
• One should encourage the patients’ responsibility up to a certain point and be 
realistic about treatment goals. 
• If the patient expresses guilt or shame, either verbally and non-verbally, one 
should not confirm the emotion by telling the patient that you understand that 
the patient feels ashamed. Such a strategy may only enhance the feeling of 
shame because it may convey to the patient that he or she ought to feel 
ashamed. One may use one’s authority to normalize such emotions by telling 
the patient that you know that it can be difficult sometimes and that in your 
experiences other patients have felt the same. 
 
Patient education and counseling should be based on recognition of the patient as the 
authority on his or her own life (145). Nevertheless, doctors may experience ethical 
dilemma when patients make very unfortunate choices and there is a conflict 
between autonomy and the principle of benevolence. Patients who are competent 
have the right to make unfortunate decisions concerning their own health, but it is 
legitimate for the doctor to give information and check that the patient has 
understood the possible consequences of a decision.  
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 As patients have different values and preferences, information about a 
patient’s health-related preferences may be included in the patient’s medical records. 
Personal continuous health care is linked with increased patient satisfaction (146, 
147), and systems which promote continuity of care will probably foster mutual 
understanding and common ground for decision-making in management of 
cardiovascular risk. 
 
5.6.  Variation and medical evidence in a genomic age 
An individualized approach communication and management of cardiovascular risk 
does not necessarily conflict with an evidence-based approach in health care (148), 
but I think our research indicates the need for a wide concept of evidence in clinical 
practice. Narrative evidence from the patient’s family history needs to be considered 
together with statistical group evidence about risk factors, effect of treatment and 
prognosis. There is, nevertheless, a potential tension between an individualized 
approach and current ideologies that emphasize evidence from randomized 
controlled trials, standardization of health care, guidelines for clinical practice, and 
clinical governance (149-150). FH calls for an individualized risk assessment and 
management, and is perhaps an extreme case – a true zebra. Perhaps the zebra can 
teach us something about management of horses? Guttmacher & Collins claim that 
all physicians need to understand the concept of genetic variability, and that the 
practice of medicine has entered an area in which the individual patient’s genome 
will help determine the optimal approach to care (1). Cassell claims that there exists 
a tension in contemporary medicine between different notions of clinical evidence: 
“Withdrawal from the patient is rewarded with certainty and punished with sterile 
inadequate knowledge; movement towards the patient is rewarded with knowledge 
and punished with uncertainties. The fact remains, however, that to disengage from 
the patient is to lose the ultimate source of knowledge in medicine.” (151). Will 
genomic medicine bring us into a situation where the movement towards the 
individual patient is rewarded with both adequate knowledge and certainty?  
 Genomic medicine is in its wake, and I do not know if it will fulfill all its 
promises. So far, patients’ family history, though it is far from a perfect tool, is one 
of strongest and most easy accessible tools clinicians may use to get hints about a 
patients hereditary disposition to disease (127, 129, 152). Variation, whether it is 
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due to a patient’s genome, life situation, values or preferences, calls for a 
multifaceted concept of evidence in clinical medicine. McWhinney’s statement that 
medicine is “a science of particulars” seems to hold true also in tomorrow’s 
medicine (108). 
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6.  CONCLUSION  
 
 
In conclusion, this thesis suggests:  
 
• When doctors and health professionals communicate about cardiovascular 
risk, they should take into account that patients’ notion of risk may differ 
from medical notions of risk and recognize that patients may have moral and 
psychological reasons for distancing themselves from the typical image of 
the “coronary candidate”. 
 
• The stereotype of CHD as a men’s disease may result in barriers to diagnosis 
and treatment for women, and the issue of gender in relation to CHD should 
warrant more attention in clinical practice and public health. 
 
• Doctors need to be sensitive to the patient’s family history of CHD and 
examine the patient about CHD in the family if a concern about 
cardiovascular risk is on the patient’s agenda. 
 
• In order to individualize clinical management, doctors should communicate 
with patients in ways that elicit patients’ understanding of risk and the factors 
that influence their perceived personal vulnerability to CHD.  
 
• Recognition of patients’ preferences and readiness for lifestyle counseling 
may reduce doctors and health professionals’ risk of unintentionally inducing 
guilt and shame in patients, and health professionals should use 
communicative strategies that diminish such feelings in their patients. 
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7.  FUTURE RESEARCH 
 
 
Our study suggests that there is need for research that:   
 
• Explore how doctors reason about cardiovascular risk, and how doctors’ 
notions of coronary candidates may influence clinical management. 
 
• Investigate how coronary candidates are portrayed in the public. 
 
• Investigates how individuals recount and perceive their family histories of 
common diseases.  
 
• Explore how information from patients’ family histories are recorded, 
interpreted, and managed in clinical practice.  
 
• Develop and evaluate methods and tools for recording and interpreting 
family history information in clinical practice. 
 
• Explore how doctors communicate about cardiovascular risk, and what 
strategies and forms of evidence they use to individualize clinical 
management.  
 
• Develop and evaluate methods and tools for dialogic and patient-centred 
communication about risk and patient counselling. 
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APPENDIX A – DIAGNOSTIC CRITERIA 
 
 
 
 
 
 
 
 
 
The Simon Brome Register Group definition of FH 
 
Criteria  
A. Total cholesterol > 7.5 mmol/l (adults) or a total cholesterol level > 6.7 mmol/l 
(children < 16) or LDL-cholesterol level > 4.9 mmol/l (adults) or a > 4.0 mmol/l 
(children < 16 years) 
B. Tendon xanthomas in patient or any of the patients’ first or second degree relatives 
C. DNA-based evidence of an LDL-receptor mutation or familial defective apo B-100 
D. Family history of myocardial infarction before the age of 50 years in grandparent, 
aunt, uncle or before the age 60 years in parent, sibling or child 
E. Family history of raised total cholesterol in parent sibling or child, or level above 
7.5 mmol/l in grandparent, aunt, uncle 
 
Diagnosis:                        Criteria required 
Definite FH                      A + B or C 
Probable FH                     A + D or A + E 
 
Adopted from ref. 20 and 23 
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Dutch Lipid Network clinical criteria for diagnosis of FH 
 
1. Family history: A first-degree relative (a parent or offspring or sibling of the 
patient) with known: 
    A) Premature coronary and vascular disease (< 55 yrs men; < 60 yrs women) 
    B) LDL-cholesterol concentration > 95th percentile for age and gender 
       i) In adult relative 
       ii) In a relative < 18 years of age 
    C) Tendon xanthomata or arcus cornealis 
 
2. Clinical history: Patient has a premature (< 55 years men; < 60 years women) 
    A) Coronary event 
    B) Cerebral or peripheral disease 
 
3. Physical examination of the patient 
    A) Tendon xanthomata 
    B) Arcus cornealis in patient < 45 years of age 
 
4. LDL-cholesterol levels in patients’ blood (mmol/L) 
    A) > 8.5 
    B) 6.5-8.4 
    C) 5.0-6.4 
    D) 4.0-4.9 
 
5. DNA analysis showing functional mutation in the LDL- receptor gene 
 
Diagnosis            Total points  
Definite FH           > 8  
Probable FH          6-8 
Possible FH           3-5                 
 
Adopted from ref. 20 and 23 
Points 
 
 
1 
 
1 
2 
2 
 
 
2 
1 
 
 
6 
4 
 
 
8 
5 
3 
1 
 
8 
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APPENDIX B – PARTICIPANTS  
 
 
 
 
Characteristics of participants (N = 40) 
 
Characteristic No. (%) 
Age, years    
  10-19 9 (22,5) 
  20-29 10 (25) 
  30-39 9 (22,5) 
  40-49 8 (20) 
  50 + 4 (10) 
 
Gender 
  
  Male 20 (50) 
  Female 20 (50) 
 
Use of lipid-lowering medication 
35 (88) 
 
Symptoms of coronary heart disease 
7 (18) 
 
Children  
   
  No 21 (52,5) 
  Yes 19 (47,5) 
 
Occupation 
  
  Professional or higher managerial 7 (17,5) 
  Other non-manual 7 (17,5) 
  Skilled manual 4 (10) 
  Manual 7 (17,5) 
  Student / secondary education 14 (23) 
  Disablement benefit 1 (0) 
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APPENDIX C – INTERVIEW GUIDE 
Sociodemographic questions  
Age 
Civil status 
Education and work experience 
Family 
Previous illness experiences? 
Previous experiences with the health service and health professionals? 
Membership in patients’ organizations? 
 
Understanding of health and disease 
What does the word health mean to you?  
How do people stay healthy? 
Why do some people have better health than others?  
Are people able to have control with their own health? 
What does fate mean to you?  
Do you have a religious perspective on issues related to health and disease? 
 
The condition 
How did you get this and how were you diagnosed? 
Do you have any symptoms, ailments, pains, of anything that limits your daily 
activities? 
What influences how your condition will develop?  
How will this condition influence your own future health?  
To what extent are you able to influence how it develops?  
 
Understanding of risk/own vulnerability to disease 
What are the risks/uncertainties connected with your condition?  
How do you estimate your own vulnerability of developing coronary heart disease?  
Have the way you think about your own vulnerability to heart disease changed?  
What does the risk mean for you personally? 
What can you do to influence your risks?  
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Do you make any efforts at reducing your risk? 
 
Experiences with the health service 
How has your contact with the health service been?  
How can health professionals help you managing your condition?  
What do you think about the information you have been given?  
Can health professional influence how you perceive your risk?  
 
The psychosocial context  
Has the condition influenced your quality of life? 
Have you talked with people outside your family about your condition?   
Can you give any examples of issues you would talk about?  
How does your family and friends manage your condition?  
How do you think other people perceive your condition? (health professionals, 
friends, family, people in general) 
 
Sources of knowledge / media  
What do you think about how your condition is portrayed in the media? 
How does information in the media influence how you understand your condition?  
Do you seek knowledge through other sources?  
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APPENDIX D – LIST OF CODES 
 
Religion/destiny/control 
Death 
Time 
Body  
Luck/bad luck 
Perception of health 
Cholesterol 
Risk 
Views concerning causes of heart disease 
Family history 
Coronary candidates  
Gender 
Medical knowledge  
Definition of FH  
Beliefs about own influence on health 
 
Motivation for preventive health behaviour 
Social relations (support or conflicts) 
Distancing and resistance  
Management of lifestyle factors  
Medication (effects/side-effects) 
Relatives  
Children  
Stigma  
Guilt  
Psychological reactions  
Genetic and clinical testing Experiences 
with health professionals 
Uncertainty 
The health service 
Complementary treatment 
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PAPERS I-IV (web-links) 
 
Paper I (full text)  
Paper I (abstract in PubMed) 
 
Paper II (full text) 
Paper II (abstract in PubMed) 
 
Paper III (full text) 
Paper III (abstract in PubMed) 
 
Paper IV (full text) 
Paper IV (abstract in PubMed) 
 
